10-Q: Nutra Pharma Corp. Q3 2025 Financials Show Increased Net Loss

Nutra Pharma Corp. reported a wider net loss for the third quarter and first nine months of 2025, driven by increased operating expenses and fluctuations in derivative liabilities, despite a rise in net sales to unrelated customers.

Summary

• Nutra Pharma Corp. reported a net loss of $523,520 for the three months ended September 30, 2025, an increase from $260,683 in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $1,558,866, up from $1,054,756 in the prior year.
• Net sales to unrelated customers increased by 39.11% to $228,748 for the nine months ended September 30, 2025, compared to $164,436 in the same period of 2024. However, net sales to related party Avini Health decreased by 3.48% to $102,493.
• Operating expenses rose significantly, with selling, general, and administrative expenses increasing by 64.67% to $420,652 for the third quarter and by 40.06% to $1,204,959 for the nine-month period, primarily due to higher consulting and professional fees.
• Interest expense, including related party interest, increased by 43.41% for the quarter and 26.08% for the nine-month period, largely due to increased amortization of loan discounts.
• The company continues to face substantial doubt regarding its ability to continue as a going concern, with a working capital deficit of $16,377,977 and a stockholders deficit of $16,350,780 as of September 30, 2025.
• The company estimates it will require approximately $1,200,000 to fund operations over the next twelve months.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, rising operating expenses, and the continued substantial doubt regarding the company's ability to continue as a going concern, despite some revenue growth.

Positives

• Net sales to unrelated customers increased by 39.11% for the first nine months of 2025 compared to the same period in 2024.
• Gross profit for the nine months ended September 30, 2025 was $208,535, an increase from $160,735 in the prior year, with a gross profit margin of 62.96% compared to 59.40%.

Negatives

• Net loss for the three months ended September 30, 2025 increased by 100.83% to $523,520 compared to the prior year.
• Net loss for the nine months ended September 30, 2025 increased by 47.79% to $1,558,866 compared to the prior year.
• Selling, general, and administrative expenses increased significantly by 64.67% for the quarter and 40.06% for the nine-month period.
• The company has a working capital deficit of $16,377,977 and a stockholders deficit of $16,350,780 as of September 30, 2025.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Several promissory notes and convertible promissory notes are in default as of September 30, 2025.

Risks

• The company has recurring significant losses from operations and an accumulated deficit of $77,790,003, raising substantial doubt about its ability to continue as a going concern.
• The company has a significant amount of indebtedness in default.
• The company does not have sufficient cash to sustain operations for the next twelve months and requires additional financing.
• The company's common stock is on the OTC Market Groups Expert Market, limiting its ability to raise capital.
• Failure to compete effectively in the biotechnology industry could negatively impact operations and market position.
• Failure to successfully execute planned partnering and out-licensing of products or technologies will adversely affect future performance.
• The economic downturn and related credit and financial market crisis may adversely affect the company's ability to obtain financing and conduct operations.
• Biotechnology industry litigation is substantial and may continue to rise, leading to greater costs and unpredictable litigation.
• Failure to comply with extensive legal/regulatory requirements affecting the healthcare industry could result in increased costs, penalties, and business losses.
• The company is subject to risks detailed in Item 1(a) of the filing (not provided in the excerpt).

Future Outlook

The company estimates it will require approximately $1,200,000 to fund its existing operations over the next twelve months, covering compensation, consulting fees, office expenses, insurance, and legal/accounting services. Future revenues from product sales are critical to covering operating expenses, and insufficient sales may necessitate raising additional equity capital, potentially leading to shareholder dilution. The company may also seek additional loans from officers and directors.

Management Comments

• The company is currently expanding production capacity in its facility to allow spot production of its products and private label brands.
• The company believes its Nyloxin products offer a safe and effective alternative to opioid and NSAID-based pain relievers.
• The company is pursuing international drug registrations and seeking new distribution partners.
• The company is working with consultants to develop trial protocols for a Phase I/II trial for RPI78M in the treatment of Pediatric Multiple Sclerosis, aiming to initiate these trials in 2026.
• The company has incurred significant losses from operations and working capital and stockholders deficits, raising substantial doubt about its ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that Nutra Pharma Corp. operates in the biotechnology and pharmaceutical sector, focusing on pain relief products and drug discovery. The company's reliance on homeopathic remedies and its drug candidates for neurological disorders place it in a highly competitive and regulated industry. The increasing scrutiny on opioid-based pain relievers presents an opportunity for alternative treatments like Nyloxin, but the company's financial precariousness and ongoing litigation pose significant challenges to its growth and development plans.

Comparison to Industry Standards

• The company's net loss for the nine months ended September 30, 2025, of $1,558,866, contrasts sharply with the profitability of many established pharmaceutical companies in the pain management sector.
• The significant increase in operating expenses, particularly consulting and professional fees, is a concern when compared to industry benchmarks for companies of similar size and stage, suggesting potential inefficiencies or a heavy reliance on external expertise.
• The company's cash balance of $3,603 as of September 30, 2025, is critically low compared to industry standards, where companies typically maintain substantial cash reserves to fund R&D, clinical trials, and market expansion.
• The substantial amount of indebtedness in default and the overall debt-to-equity ratio are significantly higher than typical industry standards for healthy biotechnology firms, indicating a high financial risk profile.

Legal Proceedings

• CSA 8411, LLC v. Nutra Pharma Corp.: A lawsuit to recover $100,000 allegedly owed under an amended promissory note. A settlement agreement was entered into on May 19, 2025, resolving the obligation for $125,000, with payments structured over nine months.
• Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus: A lawsuit alleging fraud and violations of securities laws related to private placements, press releases, and public filings. A final judgment was issued in July 2024, ordering the defendant to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty. As of September 30, 2025, $680,235 was accrued for legal settlement.
• Marc Weller v. Nutra Pharma Corporation: Litigation resolved in January 2026 through a settlement agreement where outstanding notes with a carrying value of approximately $175,000 were cancelled in exchange for $20,000 cash and 60,000,000 shares of common stock.

Related Party Transactions

• Sales to Avini Health (Avini), a company where the former CEO is an owner and chief scientific officer, decreased by 3.48% for the nine months ended September 30, 2025, compared to the prior year.
• Avini Health agreed to forgive a total of $240,557 in debt during 2024, which was accounted for as a capital contribution.
• The company owes its former director, Rik Deitsch, accrued interest of $196,876 as of September 30, 2025, related to a loan originally from 2010.
• The company recognized $5,000 in other income during the second quarter of 2025 from a related party for the shared use of equipment.

Stakeholder Impact

• Shareholders may experience dilution if the company needs to raise additional equity capital.
• Creditors face increased risk due to the company's defaults on several promissory notes and convertible promissory notes.
• Employees and consultants may be concerned about the company's going concern status and its ability to meet payroll and contractual obligations.
• Suppliers may face payment delays or uncertainty given the company's liquidity challenges.

Next Steps

• Initiate Phase I/II trials for RPI78M in the treatment of Pediatric Multiple Sclerosis in 2026.
• Continue to seek additional financing to fund operations and reduce debt.
• Negotiate settlements for outstanding promissory notes and convertible promissory notes that are in default.
• Expand production capacity for spot production of products and private label brands.

Key Dates

Recommendation

The company's financial condition, characterized by increasing net losses, substantial debt, defaults, and significant doubt about its ability to continue as a going concern, presents a high-risk investment profile. Despite some revenue growth in unrelated sales, the overall financial trajectory and operational challenges suggest a negative outlook for the stock.

Keywords

Nutra Pharma Corp, Form 10-Q, Quarterly Report, Financial Statements, Net Loss, Operating Expenses, Convertible Notes, Going Concern, Biotechnology, Pain Relief Products